⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.
ALKYLAMINE - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 3.6
| Stock Code | ALKYLAMINE | Market Cap | 6,927 Cr. | Current Price | 1,352 ₹ | High / Low | 2,449 ₹ |
| Stock P/E | 38.3 | Book Value | 282 ₹ | Dividend Yield | 0.74 % | ROCE | 18.7 % |
| ROE | 14.0 % | Face Value | 2.00 ₹ | DMA 50 | 1,484 ₹ | DMA 200 | 1,723 ₹ |
| Chg in FII Hold | 0.01 % | Chg in DII Hold | 0.13 % | PAT Qtr | 42.3 Cr. | PAT Prev Qtr | 42.9 Cr. |
| RSI | 40.1 | MACD | -66.6 | Volume | 96,293 | Avg Vol 1Wk | 94,652 |
| Low price | 1,212 ₹ | High price | 2,449 ₹ | PEG Ratio | -6.37 | Debt to equity | 0.00 |
| 52w Index | 11.3 % | Qtr Profit Var | -3.43 % | EPS | 35.3 ₹ | Industry PE | 25.7 |
📊 Financials
- Revenue & Profitability: PAT declined slightly from ₹42.9 Cr. to ₹42.3 Cr., showing -3.43% variation. EPS at ₹35.3 is modest relative to valuation.
- Margins & Returns: ROCE at 18.7% and ROE at 14.0% are decent but below top-tier benchmarks.
- Debt & Liquidity: Debt-to-equity ratio of 0.00 indicates a debt-free balance sheet, ensuring financial stability.
- Cash Flow: Dividend yield of 0.74% provides modest shareholder returns.
💹 Valuation
- P/E Ratio: 38.3 vs Industry PE of 25.7 — trading at a premium valuation.
- P/B Ratio: Current price ₹1,352 vs Book Value ₹282 — ~4.8x book value, moderately expensive.
- PEG Ratio: -6.37 — negative PEG indicates poor growth outlook relative to valuation.
- Intrinsic Value: Current price is above fair value, offering limited margin of safety.
🏢 Business Model & Competitive Advantage
- Specializes in aliphatic amines with strong niche positioning in chemicals.
- Debt-free structure enhances resilience and financial flexibility.
- Moderate returns suggest limited competitive edge compared to larger peers.
📈 Entry Zone & Long-Term Guidance
- Entry Zone: Attractive accumulation range between ₹1,210 – ₹1,300, near its 52-week low.
- Long-Term Holding: Fundamentals are average, valuations stretched. Suitable for cautious accumulation on dips with long-term horizon.
✅ Positive
- Debt-free balance sheet ensures financial stability.
- DII holdings increased by 0.13%, showing domestic institutional confidence.
- EPS of ₹35.3 reflects steady earnings capacity.
⚠️ Limitation
- High P/E ratio (38.3) compared to industry average.
- Negative PEG ratio (-6.37) indicates poor growth outlook.
- Quarterly PAT decline shows earnings weakness.
📉 Company Negative News
- RSI at 40.1 and MACD negative (-66.6) reflect bearish technical signals.
- Quarterly profit variation (-3.43%) indicates stagnation in earnings.
📈 Company Positive News
- Debt-free balance sheet enhances resilience.
- FII holdings increased slightly (+0.01%), showing foreign investor interest.
- DII holdings increased, reflecting domestic institutional confidence.
🏭 Industry
- Chemicals sector benefits from industrial demand and specialty applications.
- Industry PE at 25.7 is lower than company’s valuation, highlighting relative overpricing.
🔎 Conclusion
ALKYLAMINE shows moderate fundamentals with debt-free stability and steady earnings, but suffers from high valuations and weak growth outlook. While institutions show cautious confidence, profitability stagnation raises concerns. Best strategy: accumulate cautiously near ₹1,210–₹1,300 and hold for long-term gains, but monitor growth trajectory closely.